| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/07/2005 | US20050148582 N-[1-butyl-4-piperidinylmethyl[3,4-dihydro-2 oxazino[3,2-a indole-10 carboxamide as drugs with Cahpo4 or Ca3/po4/2 fillers or binders for use in treatment of irritable bowel syndrome, urinry incontience or arrhythmias |
| 07/07/2005 | US20050148578 1H-8-oxa-1-aza-dibenzo[e,h]azulene; dual inhibitors of tumour necrosis factor(alpha) and interleukin 1; antiinflammatory, analgesics |
| 07/07/2005 | US20050148577 2-methyl-1,8-dioxa-dibenzo[e,h]azulene; potentiation; dual inhibitors of tumour necrosis factor(alpha) and interleukin 1; antiinflammatory, analgesics |
| 07/07/2005 | US20050148576 Dibenzo[b.f]oxazolo-azulines, -oxepines and -thiepines; antiinflammatories; analgesics |
| 07/07/2005 | US20050148575 (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury |
| 07/07/2005 | US20050148572 2-(2,4-difluorophenyl)-2-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-isobutyl-2,5-dioxopiperazin-1-yl]-N,N-dimethylethanamide; to suppress uterine contractions; cyclization of leucine analogs |
| 07/07/2005 | US20050148549 Compositions and methods for inhibition of phospholipase a2 mediated inflammation |
| 07/07/2005 | US20050148548 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors |
| 07/07/2005 | US20050148537 Immunostimulatory nucleic acid molecules |
| 07/07/2005 | US20050148526 Methods of obtaining isoform specific expression in mammalian cells |
| 07/07/2005 | US20050148525 Nucleic acid markers |
| 07/07/2005 | US20050148524 Treating multiple myeloma via administering thalidomide and topoisomerase inhibitor such as irinotecan; side effect reduction |
| 07/07/2005 | US20050148521 Coadministration with non-steroidal antiinflammatory agent allows for lower dosage of cyclophosphamide; side effect reduction; kits |
| 07/07/2005 | US20050148515 Peptidomimetics; determining ability to bind growth hormone secretagogue; ghrelin agonists; appetite stimulation; dietetics |
| 07/07/2005 | US20050148513 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 07/07/2005 | US20050148504 Cysteine protease inhibitor |
| 07/07/2005 | US20050148502 Compositions and methods for preventing and treating cancer via modulating ube1l, isg15 and/or ubp43 |
| 07/07/2005 | US20050148501 Methods of inducing ovulation using a non-polypeptide camp level modulator |
| 07/07/2005 | US20050148498 Metalloprotease inhibiting activity, in particular collagenase and gelatinase, treating humans or mammals suffering from a condition or disease related to excessive degeneration of support by a metalloprotease; treat inflammatory diseases: arthrosis, parodontosis or ulcers |
| 07/07/2005 | US20050148497 Method for administering glp-1 molecules |
| 07/07/2005 | US20050148075 With binding specificity for target nucleotides containing one or GNN triplets; regulating gene expression |
| 07/07/2005 | US20050148062 Transgenic microorganisms comprising apoptosis associated genes for use as tools in identifying modulators for prevention and treatment of cell proliferative disorders |
| 07/07/2005 | US20050148058 Protein stabilization |
| 07/07/2005 | US20050148034 Using reduced microvessel outgrowth of pluripotent stem cells as diagnostic indicator angoigenseis inhibition; antitumor agents |
| 07/07/2005 | US20050148014 Regulation of human P2Y1-like G protein-coupled receptor |
| 07/07/2005 | US20050148013 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 07/07/2005 | US20050147680 Injectable veterinary composition for small animals |
| 07/07/2005 | US20050147674 A tablet or capsule prepared from a mixture of crystalline escitalopram oxalate having a median particle size of > 40 mu m and excipients; large particle size for use in direct compression; controlled crystallization from solution to avoid granulation and drying steps; binder-and lactose-free |
| 07/07/2005 | US20050147670 Oral disintegrating dosage forms |
| 07/07/2005 | US20050147649 Method and dietary composition for improving fat digestibility |
| 07/07/2005 | US20050147629 Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant |
| 07/07/2005 | US20050147619 Anion exchange resin adsorbed fraction immunopotentiator and promoter for recovery from loaded stress originating in matsutake mushroom |
| 07/07/2005 | US20050147592 Correcting underlying genetic defect; delivering heterologous gene encoding metabolic protein causing transduction of cells resulting in expression from transformed cell genetics |
| 07/07/2005 | US20050147583 Carbamylation to form a water soluble prodrug that has a biologically active agent linked to a water soluble non-immunogenic polymer; a hydrolyzing through carbamate bond; drug delivery; no enzymes or catalysts needed for release of acitve agent |
| 07/07/2005 | US20050147563 Imaging lymph nodes with a Gadolinium complex of 10-[2-hydroxy-4-aza-5-oxo-7-aza-7-(perfluorooctylsulfonyl)-nonyl]-1,4,7-tris (carboxymethyl)-1,4,7,10-tetraazacyclododecane; in vivo contrast media in nuclear spin tomography; blood-pool agents, lymphographic agents |
| 07/07/2005 | CA2551546A1 Preventive/remedy for cancer |
| 07/07/2005 | CA2551181A1 Glycosaminoglycan (gag) mimetics |
| 07/07/2005 | CA2550482A1 Vaccine comprising an angiomotin or a polynucleotide encoding an angiomotin and its uses for the treatment of angiogenic-related disorders |
| 07/07/2005 | CA2550064A1 Methods of treating acute inflammation in animals with p38 map kinase inhibitors |
| 07/06/2005 | EP1550727A1 Novel macrophage foam cell formation inhibitor fka-25 and p rocess for producing the same |
| 07/06/2005 | EP1550722A1 Serotype of adenovirus and uses thereof |
| 07/06/2005 | EP1550720A1 Mutated androgen receptor, cancer cells expressing the same, method of constructing the same and use thereof |
| 07/06/2005 | EP1550674A1 Chitosan-containing polysaccharide, process for producing the same and use thereof |
| 07/06/2005 | EP1550668A1 Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same |
| 07/06/2005 | EP1550667A1 Tyrosinase activity controlling agents, process for producing the same and external preparations containing the same |
| 07/06/2005 | EP1550662A1 Novel adenine compound and use thereof |
| 07/06/2005 | EP1550660A1 Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
| 07/06/2005 | EP1550655A1 Bicyclic intermediates |
| 07/06/2005 | EP1550651A1 Glycerol derivative |
| 07/06/2005 | EP1550463A1 Preparation for facilitating site-specific gene conversion and preparation for gene therapy |
| 07/06/2005 | EP1550462A1 Remedy or preventive for kidney disease and method of diagnosing kidney disease |
| 07/06/2005 | EP1550461A1 Remedy for chronic disease |
| 07/06/2005 | EP1550459A1 Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use |
| 07/06/2005 | EP1550449A1 Antitumor agents with the use of hsv |
| 07/06/2005 | EP1550448A1 Histamine release inhibitor |
| 07/06/2005 | EP1550443A1 Composition against stress-related diseases |
| 07/06/2005 | EP1550442A1 Composition for preventing/treating the expression of clinical symptom in disease caused by mitochondrial dysfunction |
| 07/06/2005 | EP1549740A2 Oligodendrocyte production from multipotent neural stem cells |
| 07/06/2005 | EP1549660A2 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 07/06/2005 | EP1549651A1 Kinase inhibitors |
| 07/06/2005 | EP1549645A1 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors |
| 07/06/2005 | EP1549640A2 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
| 07/06/2005 | EP1549634A1 Novel substituted indoles |
| 07/06/2005 | EP1549632A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions |
| 07/06/2005 | EP1549616A1 Organic acid salt of amlodipine |
| 07/06/2005 | EP1549600A1 Ketones |
| 07/06/2005 | EP1549598A1 Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif) |
| 07/06/2005 | EP1549351A1 Use of an npy y2 receptor antagonist for treating disorders related to angiogenesis |
| 07/06/2005 | EP1549349A1 Non-viral gene delivery system |
| 07/06/2005 | EP1549341A2 Novel tissue factor targeted antibodies as anticoagulants |
| 07/06/2005 | EP1549337A1 Glycosaminoglycan-dnase combination therapy |
| 07/06/2005 | EP1549322A2 Lipid a and other carbohydrate ligand analogs |
| 07/06/2005 | EP1549320A1 Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies |
| 07/06/2005 | EP1549319A2 Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use |
| 07/06/2005 | EP1549306A1 Substituted phenylsulfonamide inhibitors of beta amyloid production |
| 07/06/2005 | EP1549302A1 Gastrointestinal compositions comprising gaba derivatives |
| 07/06/2005 | EP1490315A4 Controlling chemical reactions by spectral chemistry and spectral conditioning |
| 07/06/2005 | EP1373256B1 Ccr5 antagonists useful for treating aids |
| 07/06/2005 | EP1307188A4 Cannabinoid drugs |
| 07/06/2005 | EP1301187B1 Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
| 07/06/2005 | EP1239862B1 Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating tumor diseases |
| 07/06/2005 | EP1230375B1 Inhibiting gene expression with dsrna |
| 07/06/2005 | EP1140909B1 Novel inhibitors of farnesyl-protein transferase |
| 07/06/2005 | EP1044001B1 Integrin receptor antagonists |
| 07/06/2005 | EP0817846B1 Intracellular domain of the her-2/neu protein for prevention or treatment of malignancies |
| 07/06/2005 | EP0730651B1 Surface loop structural analogues of fibroblast growth factors |
| 07/06/2005 | CN1636154A Di-substituted iminoheterocyclic compounds |
| 07/06/2005 | CN1636070A Nucleic acid encoding a G-protein-coupled receptor, and uses thereof |
| 07/06/2005 | CN1636067A TACIs and BR3 polypeptides and uses thereof |
| 07/06/2005 | CN1636061A Novel serine protease genes related to DPPIV |
| 07/06/2005 | CN1636016A Methods to inhibit viral replication |
| 07/06/2005 | CN1636012A Nucleotide and amino acid sequences of oocyte factors for altering ovarian follicular growth in vivo or in vitro |
| 07/06/2005 | CN1636011A Succinoylamino lactams as inhibitors and as a beta protein production |
| 07/06/2005 | CN1636007A Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases |
| 07/06/2005 | CN1636006A Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide HIV protease inhibitors |
| 07/06/2005 | CN1636005A Benzothiazinone and benzoxazinone compounds |
| 07/06/2005 | CN1636004A Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives |
| 07/06/2005 | CN1636003A Vitamin D3 derivatives and remedies using the same |
| 07/06/2005 | CN1635979A IL-8 receptor antagonists |
| 07/06/2005 | CN1635923A Enhancing therapeutic effectiveness of nitric oxide inhalation |